MYLAN DUBLIN DIVISON OF MC DERMOTT LABORATORIES L.

Company Type: Manufacturer (Factory)

Company Introduction:

The name MYLAN DUBLIN DIVISION OF MC DERMOTT LABORATORIES L. historically refers to the foundational operations of Mylan in Ireland. However, when considering Mylan's presence in India, the company operates predominantly as a Manufacturer.

Mylan India, largely formed through the acquisition of Matrix Laboratories, is a substantial pharmaceutical manufacturing enterprise. It manages numerous large-scale, technologically advanced manufacturing facilities located across India. These facilities are dedicated to the production of a wide array of pharmaceutical products, including active pharmaceutical ingredients (APIs), generic medications, specialty drugs, and biosimilars. Mylan's operations in India are a critical global hub for research, development, and the supply of affordable, high-quality medicines to international markets, in addition to serving the domestic market within India. Consequently, Mylan's activities in India are primarily centered on manufacturing.

MYLAN DUBLIN DIVISION OF MC DERMOTT LABORATORIES L. (now part of Viatris) produces or sells a wide range of pharmaceutical products in India, primarily focusing on generic and biosimilar medicines across various therapeutic areas. Key products include:

Cardiovascular: Atorvastatin, Amlodipine, Metoprolol, Lisinopril

Central Nervous System: Gabapentin, Pregabalin, Donepezil

Oncology (Biosimilars): Trastuzumab, Rituximab, Bevacizumab

Anti-infectives: Various antibiotics, antivirals, and antiretrovirals for HIV/AIDS

Gastrointestinal: Pantoprazole, Omeprazole

Diabetes: Metformin

Respiratory: Salbutamol, Fluticasone

Pain Management: Ibuprofen, Naproxen

The company's portfolio also extends to other therapeutic areas, offering a broad selection of generic prescription and over-the-counter medications.